Physician profile
Michael D Wells
NPI 1124088125
$6,454.42
in general payments reported to CMS, 2019-2025
45 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,665 · 2020: $275 · 2021: $370 · 2022: $580 · 2023: $1,057 · 2024: $1,240 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,508 · Debt Forgiveness: $56.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,508.33 |
| Debt Forgiveness | $56.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $974.28 | 2019-2025 | |
| Abbvie INC. | $914.19 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Novo Nordisk INC | $506.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $476.47 | 2019-2025 | Jardiance, Ofev, Stiolto Respimat |
| Glaxosmithkline, LLC. | $388.24 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $331.16 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $307.27 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $285.79 | 2019-2025 | Breztri, Farxiga |
| Abbott Laboratories | $227.56 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.14 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $148.40 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $147.33 | 2019-2020 | |
| Astellas Pharma US INC | $133.90 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $129.14 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $128.60 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.